$KRTL Biotech Launches Nutraceuticals Initiative i
Post# of 26114
(Total Views: 59)
Posted On: 09/30/2025 9:33:37 AM
$KRTL Biotech Launches Nutraceuticals Initiative in Partnership with SIGMA and Bolivian Health Programs
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=494106
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
is pleased to announce that its majority-owned subsidiary, KRTL Biotech, Inc., plan to lead a targeted initiative to expand its nutraceuticals portfolio as part of its recently completed merger with Industria Químico Farmacéutica SIGMA Corp SRL ("SIGMA" .
SIGMA brings more than 50 years of pharmaceutical manufacturing and commercialization experience, including a strong commitment to preventive care, functional health products, and vitamin-based therapeutics. This initiative is designed to align with government-supported wellness programs in Bolivia and support international market entry strategies for select nutraceuticals.
"The global shift toward preventive care and wellness-focused health interventions makes this a critical moment to expand our nutraceuticals capabilities," said Patricia Wilstermann, CEO of SIGMA. "We are proud to contribute decades of know-how and our product development legacy to a cause that supports both community health and commercial innovation."
Product Scope and Strategic Objectives
KRTL Biotech and SIGMA will focus on a range of vitamin supplements, functional blends, and wellness-oriented therapies that address nutritional gaps across pediatric, prenatal, adult, and geriatric populations. These formulations are manufactured under GMP-compliant protocols and supported by SIGMA’s regulatory expertise.
Initial targets for expansion include:
Multivitamin blends for immune support and nutritional balance
Vitamin and mineral formulations tailored for prenatal and senior care
Functional ingredient products that support cognitive, digestive, and cardiovascular health
Herbal and natural extracts used in traditional and integrative medicine
These products are already established in Bolivian markets and will be evaluated for export, registration, and regulatory alignment in select Latin American and U.S. jurisdictions.
"This initiative reinforces KRTL Biotech’s commitment to supporting community-based health outcomes through quality, access, and education," said Daniel Bishop, CEO of KRTL Biotech. "We are proud to begin the next phase of innovation with our SIGMA partners."
Community Impact and Global Vision
In Bolivia, SIGMA’s nutraceutical products are being deployed through national wellness campaigns aimed at sustainable, long-term health outcomes. The company collaborates with public health institutions and medical professionals to deliver accessible, science-backed solutions.
KRTL Biotech aims to amplify this success model in broader markets, using SIGMA’s established track record to launch a scalable wellness platform across Latin America and eventually North America.
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=494106
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
is pleased to announce that its majority-owned subsidiary, KRTL Biotech, Inc., plan to lead a targeted initiative to expand its nutraceuticals portfolio as part of its recently completed merger with Industria Químico Farmacéutica SIGMA Corp SRL ("SIGMA" . SIGMA brings more than 50 years of pharmaceutical manufacturing and commercialization experience, including a strong commitment to preventive care, functional health products, and vitamin-based therapeutics. This initiative is designed to align with government-supported wellness programs in Bolivia and support international market entry strategies for select nutraceuticals.
"The global shift toward preventive care and wellness-focused health interventions makes this a critical moment to expand our nutraceuticals capabilities," said Patricia Wilstermann, CEO of SIGMA. "We are proud to contribute decades of know-how and our product development legacy to a cause that supports both community health and commercial innovation."
Product Scope and Strategic Objectives
KRTL Biotech and SIGMA will focus on a range of vitamin supplements, functional blends, and wellness-oriented therapies that address nutritional gaps across pediatric, prenatal, adult, and geriatric populations. These formulations are manufactured under GMP-compliant protocols and supported by SIGMA’s regulatory expertise.
Initial targets for expansion include:
Multivitamin blends for immune support and nutritional balance
Vitamin and mineral formulations tailored for prenatal and senior care
Functional ingredient products that support cognitive, digestive, and cardiovascular health
Herbal and natural extracts used in traditional and integrative medicine
These products are already established in Bolivian markets and will be evaluated for export, registration, and regulatory alignment in select Latin American and U.S. jurisdictions.
"This initiative reinforces KRTL Biotech’s commitment to supporting community-based health outcomes through quality, access, and education," said Daniel Bishop, CEO of KRTL Biotech. "We are proud to begin the next phase of innovation with our SIGMA partners."
Community Impact and Global Vision
In Bolivia, SIGMA’s nutraceutical products are being deployed through national wellness campaigns aimed at sustainable, long-term health outcomes. The company collaborates with public health institutions and medical professionals to deliver accessible, science-backed solutions.
KRTL Biotech aims to amplify this success model in broader markets, using SIGMA’s established track record to launch a scalable wellness platform across Latin America and eventually North America.
(0)
(0)